BUSINESS WIRE
CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced that new data highlighting the
anti-angiogenic and tumor-targeting properties of TM601 will be
discussed in a poster presentation and in a published abstract at the 45th
Annual Meeting of the American Society of Clinical Oncology (ASCO),
being held May 29-June 2, 2009 in Orlando, FL. TM601 is a novel, wholly
synthetic peptide, found to have robust anti-angiogenic activity in
neovascular diseases, including cancer and ophthalmic disease.
Poster presentation #2041 is titled, “A Phase 1 evaluation of
intravenous TM601 in recurrent glioblastoma: use of perfusion MRI to
monitor anti-angiogenic effects,” and will be presented on Sunday, May
31, in the Central Nervous System Tumors General Poster Session from
8:00 am - noon ET (Level 2, West Hall C).
Abstract #e14507 titled, “A Phase 1 evaluation of intravenous (IV) 131I-chlorotoxin
delivery to solid peripheral and intracranial tumors,” was accepted for
publication on the ASCO website and is available at www.asco.org
and www.jco.org.
About TM601
TM601 is a novel, wholly synthetic peptide found to have robust
anti-angiogenic activity in neovascular diseases, including cancer and
ophthalmic disease.
For oncology applications, TM601 is highly specific and selective in
targeting both primary tumors and metastases in the periphery and in the
central nervous system. TM601 has the unique properties of highly
specific tumor cell binding, uptake and internalization. Clinical
studies confirm that TM601 targets and binds to a receptor expressed on
a wide range of tumor cells, but not on normal, healthy cells.
TransMolecular is expanding the TM601 tumor-targeting platform to
deliver a range of therapeutic agents, including novel and currently
used chemotherapeutic agents, as well as RNAi molecules, to tumor cells.
Most recently, the effects of TM601 on the neovasculature were validated
in animal models of ophthalmic disease, including wet age-related
macular degeneration (AMD).
About TransMolecular, Inc.
TransMolecular, Inc. is committed to discovering and developing novel
therapeutic products that help patients combat cancer and neovascular
diseases. TransMolecular’s product pipeline is based on the TM601
platform, a novel synthetically derived polypeptide, which has both
highly specific tumor binding properties and anti-angiogenic therapeutic
properties. More information can be found at www.transmolecular.com.
This press release contains forward-looking statements. The Company
wishes to caution the reader of this press release that actual results
may differ from those discussed in the forward-looking statements and
may be adversely affected by, among other things, risks associated with
litigation, clinical trials, the regulatory approval process,
reimbursement policies, commercialization of new technologies,
intellectual property, and other factors.